SNY Sanofi
$41.78▼ -0.02%
Healthcare
Other
Volume 155.7K
Avg Volume (10D) 3.81M
Key Metrics & Fundamentals
Market Cap
$100.11B
P/E Ratio
22.0
Div Yield
5.79%
52W Range
39.07 - 52.68
% vs 50 MA
-1.40%
% vs 200 MA
-5.93%
RSI-14
54.6
MACD Histogram
+0.3400
Beta (1Y vs SPY)
0.28
Free Cash Flow
$2.96B
Gross Rev
$12.30B
Gross Profit
$9.28B
EBITDA
$3.01B
COGS
$3.02B
Operating Exp
$6.90B
Operating Income
$2.38B
EBIT
$2.38B
Pretax Income
$837.00M
Net Income
$343.00M
EPS (Diluted)
0.15
Price & Volume History
Loading chart…
Recent News
Regeneron’s Billion-Dollar Catalyst Flying Under Wall Street’s Radar Ahead of Oct. 30 Earnings
24/7 Wall St. · Oct 26, 2026 9:39 AM ET
Novartis Reports Lower Relapse Rates and No Hy’s Law Cases in Phase 3 Remibrutinib MS Trials
InvestorsHub · Oct 26, 2026 7:52 AM ET
Novartis MS drug remibrutinib cuts relapses, no liver safety signal in trials
Investing.com · Oct 26, 2026 5:32 AM ET
These French Companies Have Global Reach. The Stocks Are Bargains.
Barrons.com · Oct 23, 2026 8:23 AM ET
Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial
Clinical Trials Arena · Oct 21, 2026 8:19 AM ET
Sanofi and ScionxBio partner on mRNA therapies
Hospital Management · Oct 21, 2026 5:37 AM ET
Sanofi and ScionxBio partner on mRNA therapies
Pharmaceutical Technology · Oct 21, 2026 5:37 AM ET
Investors pledge 230 billion euros at German summit: Merz
AFP · Oct 20, 2026 11:14 AM ET
Sanofi, ScionxBio to Develop Long-Acting xRNA Therapeutics
MT Newswires · Oct 20, 2026 10:29 AM ET
Teva Pharmaceuticals, Sanofi Report Positive 44-Week Duvakitug Data in Ulcerative Colitis, Crohn's Disease
MT Newswires · Oct 20, 2026 10:02 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See SNY's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.